Provided by Tiger Trade Technology Pte. Ltd.

Bicycle Therapeutics Limited

4.25
+0.14503.54%
Volume:88.24K
Turnover:371.28K
Market Cap:296.35M
PE:-1.55
High:4.26
Open:4.10
Low:4.10
Close:4.10
52wk High:9.16
52wk Low:3.75
Shares:69.81M
Float Shares:3.08M
Volume Ratio:1.02
T/O Rate:2.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7382
EPS(LYR):-3.1605
ROE:-32.30%
ROA:-17.91%
PB:0.58
PE(LYR):-1.34

Loading ...

European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading

MT Newswires Live
·
Yesterday

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

MT Newswires Live
·
Aug 28

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading

MT Newswires Live
·
Aug 26

European Equities Traded in the US as American Depositary Receipts Track Higher in Friday Trading

MT Newswires Live
·
Aug 21

Bicycle Therapeutics Director Charles Swanton Resigns from Board, Committees

Reuters
·
Aug 21

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live
·
Aug 19

Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

TIPRANKS
·
Aug 17

European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading

MT Newswires Live
·
Aug 17

European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading

MT Newswires Live
·
Aug 14

RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)

TIPRANKS
·
Aug 01

Bicycle Therapeutics Plc : Oppenheimer Cuts Target Price to $11 from $36

THOMSON REUTERS
·
Jul 31

Tenax Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Jul 31

U.S. Research ROUNDUP-Apple, Amazon, Mastercard

Reuters
·
Jul 31

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)

TIPRANKS
·
Jul 31

Anavex Life Sciences Q2 Net Loss Narrows on Lower R&D Costs

Reuters
·
Jul 30

Bicycle Therapeutics Posts Investor Presentation Highlighting Bicycle Molecule Platform and Oncology Pipeline

Reuters
·
Jul 30

Bicycle Therapeutics Q2 FY26 Net Loss Narrows to $50.3 Million; R&D Expenses Drop 42% to $41.2 Million

Reuters
·
Jul 30

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Jul 30

Bicycle Therapeutics Q2 Basic EPS USD -0.72

THOMSON REUTERS
·
Jul 30

Bicycle Therapeutics Q2 Net Income USD -50.333 Million

THOMSON REUTERS
·
Jul 30